Skip to main content
. 2019 May 24;112(3):266–277. doi: 10.1093/jnci/djz097

Figure 1.

Figure 1.

Expression of microRNA-27a* (miR-27a-5p) in head and neck squamous cell carcinoma (HNSCC). Quantitative real-time polymerase chain reaction (qPCR) analysis of miRNA levels from matched normal and tumor samples (n = 47) of (A) miR-27a* and (B) miR-27a (miR-27a-3p) expression in oral cavity squamous cell carcinoma (OCSCC) tumors. P values calculated by two-tailed Student t test. Error bars represent mean (95% confidence intervals [CI]). RNU 44 used as an endogenous control. C) Expression levels of miR-27a* in human papillomavirus–negative (HPV–) (n = 390) and HPV-positive (HPV+) (n = 66) HNSCC samples from The Cancer Genome Atlas (TCGA) database. Kaplan-Meier overall survival (OS) curves for (D) oropharyngeal squamous cell carcinoma (OPSCC) (n = 73) and (E) HPV+ HNSCC (n = 66) patients from TCGA expressing high miR-27a* or low miR-27a* levels; # = number. The P value was calculated using the log-rank test. (F) Expression of miR-27a* in American Joint Committee on Cancer (AJCC) stage I–II (n = 11) and stage III–IV (n = 55) HPV+ tumors in TCGA. The P value was calculated using the Mann-Whitney test. All statistical tests were two-sided.